Bernstein previews U.S. biopharma 2Q: management commentary matters more than single-quarter numbers
AI summary card
Bernstein previews U.S. biopharma 2Q: management commentary matters more than single-quarter numbers
The report covers LLY, GILD, ABBV, AMGN, MRK, BMY, PFE, and MRNA, arguing that 2Q earnings divergence is limited, but investors will focus more on Foundayo, Yeztugo, immune competition, the post-Keytruda period, cost execution, and pipeline catalysts.
- LLY is viewed as potentially having the highest share-price volatility among covered names; Bernstein expects revenue to come in slightly above consensus and is constructive on beat-and-raise, overseas Foundayo ramp-up, and commentary related to BRIDGE/BALANCE Medicare expansion.
- GILD remains Outperform, with improved pricing mix in the HIV franchise offsetting volume pressure; persistence and re-dosing behavior for Yeztugo are key watch points for incremental revenue in the second half.
- ABBV, AMGN, and PFE all face the risk of coming in slightly below consensus in 2Q, with pressure respectively from Humira/Rinvoq, Prolia/Xgeva, and COVID products plus execution concerns after the CFO departure.
- MRK's target price is raised to $105, but investors are still likely to keep pressing on Tulisokibart, the launches of enlicitide/LIPFENDRA, Keytruda durability, and M&A deployment.
- BMY is expected to deliver revenue broadly in line with expectations and EPS potentially above consensus, with focus on Milvexian, Cobenfy ADEPT, Camzyos penetration, and Revlimid erosion.
- For MRNA, single-quarter revenue is not the key issue; the real debate is about cost execution, cash burn, and major catalysts such as mRNA-1010, intismeran, norovirus, and propionic acidemia.
Report interpretation
Overview
This is Bernstein's 2Q 2026 earnings preview for its covered U.S. biopharma companies. The report notes that while whether certain companies beat expectations on quarterly revenue and EPS still matters, what is more important this quarter is management commentary on product ramp-up, full-year guidance, competitive dynamics, pipeline milestones, cost control, and capital allocation. Covered names include LLY, GILD, ABBV, AMGN, MRK, BMY, PFE, and MRNA.
Core views
The core view is that LLY and GILD offer relatively greater upside optionality in their investment stories: the former driven by its incretin franchise, overseas expansion of Foundayo, and the possibility of further guidance increases; the latter driven by its HIV franchise, persistence in Yeztugo prescriptions, and progress in oncology and liver disease pipelines. ABBV, AMGN, and PFE may post 2Q numbers slightly below market expectations, affected respectively by immune competition, declines in Prolia/Xgeva, and weakness in COVID-related products. For MRK, BMY, and MRNA, the key issue is not quarterly revenue itself, but rather subsequent growth drivers, pipeline validation, and expense/cash flow execution.
Analysis framework
The report previews each covered company one by one, comparing Bernstein's model with market consensus and incorporating recent prescription trends, regulatory approvals, clinical readouts, M&A partnerships, management communication, and product competitive dynamics to assess the likely direction of 2Q earnings deviation and key investor focus areas for the second half.
Methodology notes
Compare Bernstein's forecasts for revenue, EPS, and key product sales against market consensus.
The report assesses whether companies are likely to beat, miss, or come in inline based on positive or negative deviations, and further explains whether the gap comes from prescription trends, product mix, IPR&D, COGS, expense timing, or one-off factors.
Assess valuation impact by combining regulatory events, clinical readouts, launch timing, and management commentary.
This report particularly emphasizes that management commentary on projects such as Foundayo, Yeztugo, Keytruda SubQ, Tulisokibart, Cobenfy, and mRNA-1010 may be more important than single-quarter financial numbers in driving share prices.
Asset mapping & comparison
Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).
- LLYKey positive coverage, rated Outperform
- Strengths
- Strong incretin franchise, with Zepbound and Mounjaro expected to come in slightly above consensus; overseas market potential for Foundayo, BRIDGE/BALANCE expansion, and the December CMD provide catalysts.
- Weaknesses
- Foundayo's U.S. launch has been weaker than expected, and valuation is around 33x FY26E forward PE, clearly above the industry's typical range.
- Comparison
- The report believes its 2Q share-price volatility could be the highest among covered companies.
- Risks
- At a high valuation, any disappointment in guidance, Foundayo ramp-up, or management commentary could amplify downside.
- GILDKey positive coverage, rated Outperform
- Strengths
- Improved pricing mix in the HIV franchise, with international momentum in Biktarvy, Yeztugo, Livdelzi, and Trodelvy supporting higher full-year revenue.
- Weaknesses
- EPS below consensus is mainly due to IPR&D treatment, and third-party data have limitations in tracking Yeztugo prescriptions.
- Comparison
- Compared with most Market-Perform companies, GILD's full-year revenue forecast is above consensus and its product catalysts are clearer.
- Risks
- Yeztugo persistence and re-dosing could come in below expectations, as could BIC/LEN regulatory events or Trodelvy progress.
- ABBVRated Market-Perform, with risk of coming in slightly below consensus in 2Q
- Strengths
- Long-term growth in Skyrizi/Rinvoq remains supported; the Apogee acquisition expands the next-generation immunology pipeline; some products such as Venclexta and Linzess are above consensus.
- Weaknesses
- Humira biosimilar erosion, potential underperformance in Rinvoq and Imbruvica, and intensifying competition in immunology.
- Comparison
- Compared with LLY/GILD, ABBV's investment focus is more on defensively protecting its core immunology franchise.
- Risks
- Competition from Tremfya, Icotyde, and others could weaken Skyrizi/Rinvoq growth, while Apogee integration and pipeline projects remain uncertain.
- AMGNRated Market-Perform, with 2Q miss risk
- Strengths
- Repatha, Evenity, Uplizna, and Imdelltra may offset some pressure from mature products.
- Weaknesses
- Steeper declines in Prolia/Xgeva, regulatory uncertainty around TAVNEOS, and COGS pressure from product mix.
- Comparison
- Relative to BMY, AMGN's downside risk to 2Q EPS is more pronounced.
- Risks
- Biosimilar competition, IRS tax disputes, the new CFO transition, and execution risk in late-stage obesity/cardiometabolic pipelines.
- MRKRated Market-Perform, target price raised to $105
- Strengths
- Keytruda still has scale advantages, multiple regulatory approvals and pipeline readouts are advancing, and the Google Cloud AI partnership supports long-term efficiency.
- Weaknesses
- EPS is distorted by acquisition-related expenses, and forecasts for new growth drivers such as Winrevair and Capvaxive are more conservative than consensus.
- Comparison
- The report believes MRK still needs to prove its growth drivers beyond Keytruda.
- Risks
- Slowing Keytruda growth, the pace of SubQ conversion, Tulisokibart and sac-TMT data, enlicitide launch, and M&A capital allocation risks.
- BMYRated Market-Perform, with revenue broadly inline and EPS potentially above consensus
- Strengths
- Healthy Eliquis trends, with Camzyos penetration, Breyanzi annualized sales, Cobenfy progress, and multiple oncology/hematology programs as focus areas.
- Weaknesses
- Ongoing Revlimid erosion, and near-term forecasts for some products such as Opdualag and Cobenfy are below consensus.
- Comparison
- Compared with PFE and AMGN, BMY has relatively greater upside potential for 2Q EPS.
- Risks
- Milvexian, Cobenfy ADEPT readout, Eliquis growth durability, Qvantig conversion, and the pace of Revlimid decline.
- PFERated Market-Perform, with risk of both revenue and EPS coming in below consensus in 2Q
- Strengths
- Stable Vyndaqel trends, while the Innovent partnership and the obesity asset berobematide provide medium- to long-term optionality.
- Weaknesses
- Pressure on Paxlovid, Comirnaty, Abrysvo, and Xeljanz, while CFO Dave Denton's departure will raise execution concerns.
- Comparison
- PFE's short-term financial pressure stands out among covered companies.
- Risks
- Delivery of cost savings, COVID demand, integration of Seagen products, completion of the Innovent deal, and progress in obesity and oncology pipelines.
- MRNARated Market-Perform, with 2Q revenue not the core issue
- Strengths
- mRNA-1010, intismeran, mCOMBRIAX, oncology vaccines, and the in vivo CAR-T platform provide long-term optionality.
- Weaknesses
- Revenue is highly seasonal, the 2Q base is low, near-term commercial contribution is limited, and cash burn and cost execution remain core concerns.
- Comparison
- Compared with traditional large-cap pharma companies, MRNA's valuation depends more on validation of a small number of late-stage catalysts.
- Risks
- Commercialization timing after mRNA-1010 approval, execution in the 2026 respiratory season, norovirus readout, progress in propionic acidemia, and cash flow improvement.
Key data
- Covered company ratingsLLY/GILD are Outperform; ABBV/AMGN/BMY/MRK/MRNA/PFE are Market-PerformFrom the report's rating table and main text.
- LLY 2Q26 revenue expectation$20.688B vs consensus $20.585BBernstein expects revenue to be slightly above consensus and forecasts at least a $1.5B increase to the midpoint of full-year revenue guidance.
- LLY target price$1385The report references the full LLY 2Q preview and maintains beat-and-raise potential.
- GILD 2Q26 revenue expectation$7.52B, 1.4% above consensusYeztugo 2Q26 is expected at $232M, 2.3% above consensus.
- GILD FY26 revenue expectation$30.9B, 1.5% above consensusMainly driven by international momentum in Biktarvy, Yeztugo assumptions, and an upward revision to Livdelzi.
- ABBV 2Q26 revenue and EPS expectationsRevenue $16.6B, 0.7% below consensus; EPS $3.54, 1.6% below consensusRinvoq, Humira, and Imbruvica may weigh, while Skyrizi is broadly in line with expectations.
- AMGN 2Q26 revenue and EPS expectationsRevenue $9.3B, 1.1% below consensus; EPS $5.39, 3.6% below consensusDeclines in Prolia/Xgeva and COGS pressure are the main risks.
- MRK target price revisionTarget price raised to $105Reflects updated estimates and a more balanced DCF and P/E multiple valuation framework.
- MRK 2Q26 expectationRevenue around $16.3B, broadly in line with consensus; adjusted EPS -$0.24, below consensusEPS is heavily affected by acquisition-related expenses.
- BMY 2Q26 expectationRevenue $11.7B, 0.3% below consensus; adjusted EPS $1.65, 3.6% above consensusEPS above consensus is mainly due to a lower R&D expense assumption.
- PFE 2Q26 expectationRevenue $14.1B, 2.0% below consensus; EPS $0.66, 2.6% below consensusProjects such as Paxlovid, Comirnaty, and Abrysvo are under pressure, and the CFO departure will also prompt questions.
- MRNA 2Q26 revenue expectation$101M vs Bloomberg consensus $105MProduct revenue is expected at $58M, with the remainder from stand-ready contracts and other revenue.
Impact & implications
The investment implication is that this earnings season may not see stock prices driven solely by revenue and EPS deviations; management commentary on second-half 2026 trends is more likely to influence valuation re-rating. LLY has the highest volatility given its high valuation, strong share-price performance in 2Q, and continuing potential for guidance increases plus multiple catalysts. For GILD, the key issue is whether Yeztugo revenue layering materializes. The valuation narratives for MRK, BMY, and MRNA depend more on pipeline and new-product validation, while ABBV, AMGN, and PFE need to prove that pressure on core products is manageable and that expense and capital-allocation execution remain stable.
Risks
- 2Q revenue or EPS could come in below consensus, especially for ABBV, AMGN, and PFE.
- Management commentary may fail to support expectations for full-year guidance, product ramp-up, or cost improvement.
- Key pipeline readouts, PDUFA decisions, or regulatory events may be delayed or fail.
- Competition may intensify in immunology, HIV, oncology, vaccines, and cardiometabolic.
- High-valuation companies such as LLY are more sensitive to even small pieces of negative information.
- M&A integration, IPR&D expenses, COGS, and R&D/SG&A timing may drive EPS volatility.
What to watch
- LLY's U.S. and overseas Foundayo launch, BRIDGE/BALANCE Medicare expansion, whether full-year guidance is raised, and the December CMD.
- GILD's Yeztugo persistence and re-dosing behavior, BIC/LEN PDUFA, progress in islatravir/lenacapavir, and Trodelvy updates.
- ABBV's prescription trends for Skyrizi/Rinvoq, competition from Tremfya/Icotyde, Apogee integration, and the next-generation immunology pipeline.
- AMGN's Prolia/Xgeva declines, momentum in Repatha/Evenity/Uplizna/Imdelltra, IRS tax disputes, and the new CFO transition.
- MRK's Keytruda SubQ conversion, Tulisokibart, sac-TMT, enlicitide launch, and M&A deployment.
- BMY's Eliquis durability, Camzyos penetration, year-end Cobenfy ADEPT readout, and Revlimid erosion.
- PFE's cost savings plan, CFO transition, Innovent deal, Vyndaqel durability, and the obesity asset berobematide.
- MRNA's mRNA-1010 PDUFA, execution in the fall respiratory season, intismeran interim analysis, and readouts in norovirus and propionic acidemia.